Browse grants
Federal opportunities with plain-English eligibility summaries. We aggregate public records — always verify the details on the funder’s site before applying.
Mind and Body Interventions to Restore Whole Person Health via Emotional Well-Being Mechanisms (R61/R33 Clinical Trial Required)
Due Jun 7, 2028National Institutes of Health · Amount varies
The National Center for Complementary and Integrative Health (NCCIH) announces this Notice of Funding Opportunity (NOFO) to solicit applications for research on how mind and body interventions through psychological and/or physical inputs (e.g., mindfulness meditation, yoga, acupuncture, massage, and other brain and/or body based interventions) impact mechanisms of emotional well-being (EWB) and their associations with whole person health (WPH), consistent with the NIH priority to address the health needs of the American people and improve their well-being. The NOFO will support rigorous and well-powered mechanistic research studies that are supported by strong preliminary data. The studies should examine the effects of mind and body interventions on innovative mechanisms of EWB (as the primary outcome), as well as the associated relationship with the Whole Person Health Index (WPHI, as a secondary outcome). To enhance research safety, rigor, and efficiency of NIH-funded mechanistic clinical trials, this initiative will use a two-phased award funding mechanism (R61/R33). The funding will support an initial phase (R61) to establish feasibility benchmarks for the proposed mechanistic clinical trial(s), followed by a second phase (R33) to complete the full-scale trials, which will be contingent upon successful completion of R61 milestones. Applications should provide preliminary data that are comparable in quality and quantity to those expected for an R01 proposal.
INCLUDE Project: Clinical Trials Phased Awards for Down syndrome Research (R61/R33 Clinical Trial Required)
Due Jun 15, 2028National Institutes of Health · Amount varies
The NIH INvestigation of Co-occurring conditions across the Lifespan to Understand Down syndromE (INCLUDE) Project seeks to improve health and quality-of-life for individuals with Down syndrome. The purpose of this Notice of Funding Opportunity (NOFO) encourages Exploratory/Developmental Phased Innovation (R61/R33) grant applications to support development of clinical trials to treat critical and co-occurring health conditions in individuals with Down syndrome. The proposed research aims should be milestone-driven. The total project period for an application submitted in response to this NOFO may not exceed five years. This NOFO provides support for up to two years (R61 phase) for preliminary/developmental/planning studies, followed by possible transition to clinical trial support (R33) of up to three years, although the total duration of the award may not exceed five years. This NOFO requires measurable R61 milestones.
INCLUDE Project: Transformative Research Awards for Down syndrome (R01 Clinical Trial Not Allowed)
Due Jun 15, 2028National Institutes of Health · Up to $500K
The NIH INvestigation of Co-occurring conditions across the Lifespan to Understand Down syndromE (INCLUDE) Project seeks to improve health and quality-of-life for individuals with Down syndrome. The purpose of this Notice of Funding Opportunity (NOFO) is to solicit Transformative Research Award applications to support individual scientists or groups of scientists proposing groundbreaking, exceptionally innovative, original, and/or unconventional research that has the potential to create new scientific paradigms, establish entirely new and improved clinical approaches, or develop transformative technologies related to Down syndrome. Applications are welcome in all topics relevant to Down syndrome-related research or its co-occurring conditions. No preliminary data are required. Projects must clearly demonstrate, based on the strength of the logic, a compelling potential to produce a major impact in research related to Down syndrome.
INCLUDE Project: Exploratory/Developmental Research Awards for Down syndrome (R21 Clinical Trial Not Allowed)
Due Jun 15, 2028National Institutes of Health · Up to $200K
The NIH INvestigation of Co-occurring conditions across the Lifespan to Understand Down syndromE (INCLUDE) Project seeks to improve health and quality-of-life for individuals with Down syndrome. This Notice of Funding Opportunity (NOFO) invites researchers to submit applications for support of new exploratory and developmental research projects that address critical needs for Down syndrome projects, as articulated in the INCLUDE Project objectives. For example, such projects could assess the feasibility of a novel area of investigation or a new experimental system that has the potential to enhance health-related research. Another example could include the unique and innovative use of an existing methodology to explore a new scientific area. These studies may involve considerable risk but may lead to a breakthrough in a particular area, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of biomedical, behavioral, or clinical research.
Native American Research Centers for Health (NARCH) Planning Grants (R34 - Clinical Trial Not Allowed)
Due Jul 7, 2028National Institutes of Health · Amount varies
The purpose of the Native American Research Centers for Health (NARCH) Planning Grants program is to support federally recognized American Indian/Alaska Native (AI/AN) Tribes, Tribal colleges and universities, Tribal health programs, or Tribal organizations (collectively, eligible AI/AN Tribal entities) to plan and conduct preparatory work for developing competitive NARCH applications.
Clinical Trial Readiness for Rare Diseases, Disorders, and Syndromes (R21 Clinical Trial Not Allowed)
Due Jul 20, 2028National Institutes of Health · Amount varies
This Notice of Funding Opportunity (NOFO) invites researchers to submit applications for support of clinical projects that address critical needs for clinical trial readiness in rare diseases. The initiative seeks applications that are intended to facilitate rare diseases research by enabling efficient and effective movement of candidate therapeutics or diagnostics toward clinical trials, and to increase their likelihood of success. This could be through the development and testing of rigorous biomarkers and clinical outcome assessment measures, or by defining the presentation and course of a rare disease to enable the design of upcoming clinical trials.
BROAD AGENCY ANNOUNCEMENT (BAA) for Extramural Biomedical and Human Performance Research and Development Department of Defense
Due Jul 31, 2028Defense Health Agency Contracting Activity - DHACA · $750K–$50M
The FY23 -FY28 Broad Agency Announcement for Extramural Biomedical Research and Development - HT9425-23-S-SOC1.
Defense Security Cooperation University - Research Grants
Due Aug 7, 2028Washington Headquarters Services · $2.5K–$800K
The Defense Security Cooperation Agency’s (DSCA) Defense Security Cooperation University (DSCU) promotes access to and production of knowledge on security cooperation. Security cooperation refers to “all Department of Defense (DoD) interactions with foreign security establishments that build and develop allied and partner security capabilities and capacity for self-defense and multinational operations, provide the Armed Forces of the United States with access to the foreign country during peacetime or a contingency operation, and build relationships that promote specific United States security interests” (Joint Publication 3-20, Security Cooperation, 1-2; see also 10 USC § 16, “Security Cooperation”). Evidence-, theory, and data-building activities that contribute to the body of knowledge on security cooperation or irregular warfare, and that result in lessons that can be applied to practice, are the primary focus of this notice of funding opportunity (NFO). Research products sponsored through this NFO must be unclassified and publicly accessible. DSCU expects awardees to participate in conferences, seminars, focus groups and events, and to make final research products and supporting data (if applicable) easily accessible to the public, in order to enhance dissemination of research findings and facilitate application of lessons learned in areas of policy, practice, and workforce professionalization. The DSCU research grant program, conducted pursuant to 10 USC § 4001 and 10 USC § 384(g), is generally open to a broad range of researchers, although individual DSCU components may have restrictions on who may receive grants. Please see the full NFO for complete details.
Development of Interventions to Prevent and Treat Substance Use Disorders and Overdose (UG3/UH3 - Clinical Trial Optional)
Due Aug 21, 2028National Institutes of Health · Up to $3M
The purpose of this Funding Opportunity (NOFO) is to solicit grant applications to support research on the discovery and development of interventions to prevent and/or treat substance use disorders (SUDs) and overdose, including medications and medical devices to treat co-morbid SUDs. This includes preclinical and clinical research studies that will have high impact and quickly yield the necessary results to advance candidate interventions closer to regulatory approval or clinical adoption. This NOFO will utilize the UG3/UH3 activity code.
Transformative Non-Invasive/Minimally Invasive Technologies for Imaging the Olfactory System Across Scales (R01 CT Optional)
Due Aug 21, 2028National Institutes of Health · Up to $500K
The National Institute on Deafness and Other Communication Disorders (NIDCD), with the National Institute of Biomedical Imaging and Bioengineering (NIBIB) aims to support the development and/or adaptation of transformative in vivo high-resolution/high specificity imaging of the human olfactory system. Currently, there are limited non-invasive/minimally invasive technologies available for imaging the living human peripheral and central olfactory system with high spatial and temporal resolution. Imaging the olfactory system in the laboratory and in the clinic is essential to understanding underlying biological mechanisms as well as the etiology of an olfactory disorder. Such imaging has proven challenging due to the olfactory system"s unique anatomical and functional characteristics such as restricted accessibility, multiple cell types, and low signal resolution. Addressing these challenges requires multimodal approaches including leveraging existing advanced tools and technologies and developing new tools tailored for the olfactory system. Recent advances in minimally invasive and non-invasive imaging technologies, such as cell specific biomarkers, fluorescence imaging, specialized endoscopes, optical and acoustic imaging, molecular imaging, and hemodynamic and diffusion imaging have the potential to transform our ability to image and investigate the peripheral and central olfactory system in the living human with superior temporal and spatial resolution and eventually improve diagnostic accuracy of olfactory disorders. Applications must leverage advanced non-invasive/minimally invasive imaging technologies to visualize peripheral (e.g., olfactory- and non-olfactory epithelium) and central olfactory (e.g., olfactory bulb) targets at a level previously unattainable. In addition, projects should engage multidisciplinary teams combining expertise in olfaction, biomedical imaging, biochemistry, bioengineering, and biophysics, as appropriate.
Stephen I. Katz Early Stage Investigator Research Project Grant (R01 Clinical Trial Not Allowed)
Due Aug 25, 2028National Institutes of Health · Amount varies
The Stephen I. Katz Early Stage Investigator Research Project Grant supports an innovative project that represents a change in research direction for an early stage investigator (ESI) and for which no preliminary data exist. Applications submitted to this Notice of Funding Opportunity (NOFO) must not include preliminary data. Applications must include a separate attachment describing the change in research direction.
Vet-LIRN Capacity-Building Project and Equipment Grants (U18)
Due Sep 4, 2028Food and Drug Administration · $225K–$2.5M
The goal of this NOFO is to fund veterinary diagnostic laboratories in the Vet-LIRN network for grants associated with projects and equipment. Specific objectives include: 1. Supporting the development, adaptation, or verification/validation of new methods associated with animal food issues or antimicrobial resistance. 2. Short-term surveillance or monitoring efforts aligned with the CVM mission. 3. Supporting equipment for testing or developing tests associated with animal food-related issues or antimicrobial resistance, including those for emerging technologies. 4. Developing projects related to antimicrobial stewardship, in alignment with CVM's key initiatives in this area. 5. Contributing as part of Vet-LIRN's AMR monitoring program, including sequencing isolates. 6. Supporting work associated with One Health, including emerging diseases such as COVID-19, when funding is available.
Support for Research Excellence (SuRE) Award (R16 Clinical Trial Not Allowed)
Due Sep 7, 2028National Institutes of Health · Up to $100K
The SuRE program supports research capacity building at eligible higher education institutions by funding investigator-initiated biomedical research inbasic, social, clinical, behavioral, or translational science that falls in the mission areas of the NIH. The purpose of SuRE awards is to provide support for investigator-initiated research at resource-limited institutions by full-time faculty who are not currently funded by any NIH Research Project Grants (RPGs) with the exception of SuRE or SuRE-First awards, to furnish students with high-quality undergraduate and/or graduate research experiences, and to enhance the institutional scientific research culture.
Support for Research Excellence First Independent Research (SuRE-First) Award (R16 - Clinical Trial Not Allowed)
Due Sep 7, 2028National Institutes of Health · Up to $125K
The SuRE program supports research capacity building at eligible higher education institutions through funding investigator-initiated biomedical research inbasic, social, clinical, behavioral, or translational science that falls in the mission areas of the NIH. The purpose of SuRE-First awards is to provide support for investigator-initiated research at resource-limited institutions by full-time faculty who have not had any prior independent, peer-reviewed, external research grants, to furnish students with high-quality undergraduate and/or graduate research experiences, and to enhance the institutional scientific research culture.
Exploratory Grants in Cancer Control (R21 Clinical Trial Optional)
Due Sep 7, 2028National Institutes of Health · Amount varies
This funding opportunity announcement (FOA) encourages the submission of exploratory/developmental research grant (R21) applications that focus on different aspects of cancer control by modifying behavior, screening, and understanding etiologic factors contributing to the development of cancer, and developing ways to control cancer. The overarching goal is to provide support to promote the early and conceptual stages of research efforts on novel scientific ideas that have the potential to substantially advance population-based cancer research, such as the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of cancer research (epidemiologic, biomedical, behavioral, health care delivery or clinical).
Method to Extend Research in Time (MERIT) Award Extension Request (Type 4 eSubmission Clinical Trial Optional)
Due Sep 7, 2028National Institutes of Health · Amount varies
The National Cancer Institute (NCI) Method to Extend Research in Time (MERIT) (R37) Award provides extended grant support to Early Stage Investigators (ESIs). By providing such an opportunity for longer term support to ESIs, the NCI intends to offer flexibility and opportunity for creativity and innovation and additional time to successfully launch their careers and to become more established before having to submit renewal applications (NOT-CA-18-037). The objective of the NCI's ESI MERIT Award is to allow eligible investigators the opportunity to obtain up to 7 years of support in two segments:
Avant Garde/Avenir Awards for Investigators Conducting High Risk/High Reward Research on HIV and Substance Use (or Substance Use Disorders) (DP1 Clinical Trial Optional)
Due Sep 25, 2028National Institutes of Health · Amount varies
The purpose of this notice of funding opportunity (NOFO) is to support innovative basic, clinical, translational, and implementation science research relevant to HIV and substance use. This initiative encourages high risk high impact transformative studies that advance knowledge and strategies for HIV prevention, diagnosis, treatment and virus suppression in people who use substances and/or have a substance use disorder.
NIGMS Institutional Biomedical Undergraduate Research Training (BURT) Program (T34)
Due Sep 25, 2028National Institutes of Health · Amount varies
The goal of the Institutional Biomedical Undergraduate Research Training (BURT) program is to strengthen research training environments and develop a pool of well-trained students who:Complete their baccalaureate degrees in biomedically-related fields, andTransition into and complete biomedical, research-focused higher degree programs (such as Ph.D. or M.D./Ph.D.).Specifically, this funding announcement provides support to eligible, domestic organizations to develop and implement effective, evidence-informed approaches to biomedical undergraduate training and mentoring to help build a strong biomedical research workforce for the nation.Applicant organizations must enroll undergraduate students and have received NIH Research Project Grant (RPG) funding averaging less than $50 million in total costs (direct and F&A/indirect) per year over the last three fiscal years (FY). To promote undergraduate research training opportunities across a range of eligible organizations, the program will accept applications in two tracks:Single Site: To support trainees from a single baccalaureate-degree granting organization.Community College Partnerships: To support community college trainee development through strong collaborations between at least one associate-degree granting organization (that is, a community college) and at least one baccalaureate-degree granting organization.The proposed research training programs will incorporate didactic, research, and career development elements to prepare trainees for careers that will have a significant impact on the health-related research needs of the nation.
Cancer Center Support Grants (CCSGs) for NCI-designated Cancer Centers (P30 Clinical Trial Optional)
Due Sep 25, 2028National Institutes of Health · Amount varies
This Notice of Funding Opportunity (NOFO) invites applications for P30 Cancer Center Support Grants (CCSGs) to support NCI-Designated Cancer Centers. CCSGs support three types of Cancer Centers: 1) Comprehensive Cancer Centers, which demonstrate reasonable depth and breadth of research activities in each of three major areas: basic laboratory; clinical; and prevention, control and population-based research, and which have substantial transdisciplinary research that bridges these scientific areas; and 2) Clinical Cancer Centers, which are primarily focused on basic laboratory; clinical; and prevention, cancer control, and population-based research; or some combination of these areas, and 3) Basic Cancer Centers, which focus on basic laboratory research. The purpose of all types of NCI-Designated Cancer Centers is to capitalize on all institutional cancer research capabilities, integrating meritorious research into a single transdisciplinary research enterprise across all institutional boundaries. Cancer Centers supported through this NOFO are expected to serve as major sources of discovery of the nature of cancer and of development of more effective approaches to prevention, diagnosis, and therapy; to contribute significantly to the development of Shared Resources that support research; to collaborate and coordinate their research efforts with other NCI-funded programs and investigators; and to disseminate research findings for the benefit of the community.
Limited Competition: Superfund Hazardous Substance Research and Training Program (P42 Clinical Trial Optional)
Due Sep 25, 2028National Institutes of Health · Up to $1.8M
The National Institute of Environmental Health Sciences (NIEHS) is announcing the continuation of the Superfund Hazardous Substance Research and Training Program, referred to as Superfund Research Program (SRP) Centers. SRP Center grants will support problem-based, solution-oriented research Centers that consist of multiple, integrated projects representing both the biomedical and environmental science and engineering disciplines; as well as cores tasked with administrative (which includes Center leadership, data management, and training); translational research and engagement; and research support functions. The scope of the SRP Centers is taken directly from the Superfund Amendments and Reauthorization Act of 1986, which limits competition for this program to accredited institutes of higher education.Please see Section III. Eligibility for additional information. In accordance with NIH standard peer-review processes, the application(s) will be peer-reviewed, and only meritorious application(s) will be considered for funding.